CellOrigin Biotech Secures ￥10 Million in a New Financing Round

(VCBeat) July. 16, 2021 -- CellOrigin Biotech (Hangzhou) Co., Ltd. ("CellOrigin"), a high-tech and innovative company dedicated to the research and development of immune cells differentiated by engineering pluripotent stem cells, has officially announced the completion of a new round of funding of tens of millions of yuan to promote the development of clinical level immune cell production process and accelerate the development of other innovative products and pipelines. This round of financing is led by Kunlun Fund. Previously, CellOrigin Biotech has received investment from Shulan Junjie Capital and Nest.Bio Ventures.

CellOrigin Biotech is committed to develop a platform for differentiating genetically engineered pluripotent stem cells (iPSC) to various immune cells (such as macrophages, NK cells), with its own proprietary intellectual property. The founders are from Harvard University, Massachusetts Institute of Technology, Zhejiang University and experienced industry leaders. 

CellOrigin Biotech has developed a close collaboration with world-leading laboratories at Harvard University and Massachusetts Institute of Technology in the field of stem cell and synthetic biology. It takes the advantages of iPSC (monoclonal, genetically editable, and easily expandable), to achieve the goal of producing universal, safe, and effective immune cells on a large scale so that those off-the-shelf iPSC-derived products can be applied in immunotherapy for cancer and rare diseases in the future.

The core technology of CellOrigin Biotech -- the preparation technology of macrophages targeting tumor cells based on iPSC cells has been authorized by the national institution, and the applications of the international PCT patent in the United States, Australia, South Africa, and other countries has been filed. The technology also received IIT ethical approval for investigator-initiated clinical trials.

Kunlun Fund is a professional private equity fund (PEF) management institution focusing on energy services, new energy, rail transit, high-end equipment manufacturing, etc. Its headquarter is located in Beijing. After years of development, Kunlun Fund has been achieved outstanding performance in various fields.

Nest.Bio Ventures is a venture creation and venture capital firm focused on developing, funding, and commercializing life science companies globally. They believe in hands-on investment philosophy and roll up their sleeves alongside founders to translate high-impact science into sustainable clinical therapies.